Slide 1: 1Q 2025 Financial Results
1Q 2025 Financial Results Nasdaq: NEO April 29, 20251
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any
Slide 3: Mission and Vision
Mission We save lives by improving patient care. Vision We are becoming the world’s leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services. 3
Slide 4: 1Q 2025 Highlights
1Q 2025 Highlights Clinical Volume (unit thousands) 8% Clinical Revenue Per Test 3% 326 $465 322 $463 • Testing volumes increased 8% vs prior year $459 315 • Adjusted Gross Margin increased to 47% 312 $454 • 18% growth in Clinical NGS revenue $447 301 • AEBITDA improves 102% with 7 consecutive quart
Slide 5: Sustainable Growth – Clinical
Sustainable Growth – Clinical Increase Volumes Expand Salesforce Sign Agreements and Enhance Footprint 8% YoY Up to 140 reps Partnerships Pathline Acquisition Clinical NGS grew 18% Focused on Community EPIC Partnership to Expands Reach to • Approx. 31% of total Oncology Accelerate Integration Northe
Slide 6: Sustainable Growth – Innovation
Sustainable Growth – Innovation Launching Q2 2025 517 genes + MSI & TMB 514 genes + MSI & bTMB Tissue-based DNA + RNA sequencing ctDNA sequencing Blood-based biomarker testing biomarker testing 8-10 day TAT 7-day TAT Easy to interpret report Easy to interpret report Guideline-driven Guideline-driven
Slide 7: 1st Quarter 2025 Financial Highlights
1st Quarter 2025 Financial Highlights • Total Quarter Revenue Revenue Adj. Gross Profit Increased 8% Up 8% Up 11% • 18% revenue growth in Clinical NGS to $168M to $79M • Adjusted Gross Margin increased to 47% an improvement of 146 bps • Adjusted EBITDA increased Clinical Volume Adj. EBITDA to positi
Slide 8: 1st Quarter Revenue Results
1st Quarter Revenue Results 172 • Revenue Grew 8% to $168M 168 168 • Clinical Revenue per Test 165 Improved 3% Due to Mix and Pricing 156 156 152 • RCM Initiatives Contributing to Revenue Growth 147 137 Q1 Q2 Q3 Q4 2023 Revenue 2024 Revenue 2025 Revenue Quarterly financial information is unaudited.
Slide 9: 1st Quarter Financial Overview
1st Quarter Financial Overview Financial Statement In $Millions 1Q’24 1Q’25 %vPY Revenue $156.2 $168.0 7.5% Adjusted Gross Profit $70.8 $78.6 11.0% Adjusted Gross Margin 45.3% 46.8% 146 bps Adjusted EBITDA $3.5 $7.1 102.5% Adjusted EBITDA Margin 2.2% 4.2% 197 bps Cash and cash equivalents $331.9 $34
Slide 10: FY 2025 Guidance
FY 2025 Guidance Revised Original Guide ($ Millions) YoY% Growth ($ Millions) YoY% Growth Revenue $735 - $745 11 – 13 % $747 - $759 13 – 15 % Adj. EBIDTA $55 - $58 38 – 45 % $55 - $58 38 – 45 % Reiterating FY guidance on base business, adding in incremental revenue from Pathline acquisition of $12-1
Slide 11: Summary
Summary • Momentum continues with revenue growth of 8%, volume growth of 8%, and 102% Adj. EBITDA improvement. • Increased focus in 2025 on R&D and Business Development to drive innovation, including launch of PanTracer LBX in Q2 • Key strategic initiatives continue to drive revenue growth, operatin
Slide 12: All rights reserved
© 2024 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property of their respective owners. Rev. MMDDYY 12
Slide 13: Appendix
pas O c ® oe QO <x
Slide 14: Balance Sheet
March 31, 2025 (unaudited) December 31, 2024 ASSETS Current assets Balance Cash and cash equivalents Marketable securities, at fair value $ 346,194 11,886 $ 367,012 19,832 Sheet Accounts receivable, net 151,208 150,540 Inventories 29,772 26,748 Prepaid assets 22,980 20,165 March 31, 2025 Other curre
Slide 15: Income Statement
Three Months Ended March 31, 2025 2024 Income NET REVENUE 168,035 156,240 Statement COST OF REVENUE 94,789 90,771 GROSS PROFIT 73,246 65,469 March 31, 2025 Operating expenses: General and administrative 68,207 65,797 Research and development 10,181 7,620 (unaudited, in thousands) Sales and marketing
Slide 16: Statements of Cash Flows
Three Months Ended March 31, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Statements of Net loss $ (25,923) $ (27,061) Adjustments to reconcile net loss to net cash used in operating activities: 9,366 9,905 Depreciation Cash Flows Amortization of intangibles 8,362 10,754 8,362 7,774 March 31, 2025
Slide 17: Adjusted Gross Margin
Three Months Ended March 31, 2025 2024 % Change Adjusted Consolidated: Total revenue (GAAP) $ 168,035 $ 156,240 7.5 % Gross Margin Cost of revenue (GAAP) Adjustments to cost of revenue(6) $ 94,789 (5,325) $ 90,771 (5,305) 4.4 % March 31, 2025 Adjusted cost of revenue (non-GAAP) $ 89,464 $ 85,466 4.7
Slide 18: Adjusted EBITDA
Three Months Ended March 31, 2025 2024 Adjusted Net loss (GAAP) $ (25,923) $ (27,061) EBITDA Adjustments to net loss: Interest income (3,721) (4,834) March 31, 2025 Interest expense Income tax expense (benefit) 1,618 266 1,685 (620) (unaudited, in thousands) Depreciation 9,366 9,905 Amortization of
Slide 19: Adjusted EBITDA 2025 Guidance
Year Ended December 31, 2025 Low Range High Range Adjusted Net loss (GAAP) $ (85,000) $ (77,000) 34,000 34,000 Amortization of intangibles EBITDA 47,000 44,000 Stock-based compensation expenses 24,000 24,000 Other one-time expenses 2025 Guidance 20,000 25,000 Adjusted net income (non-GAAP) Interest